JPS6245208B2 - - Google Patents
Info
- Publication number
- JPS6245208B2 JPS6245208B2 JP56120459A JP12045981A JPS6245208B2 JP S6245208 B2 JPS6245208 B2 JP S6245208B2 JP 56120459 A JP56120459 A JP 56120459A JP 12045981 A JP12045981 A JP 12045981A JP S6245208 B2 JPS6245208 B2 JP S6245208B2
- Authority
- JP
- Japan
- Prior art keywords
- human
- cells
- necrosis factor
- htnf
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004027 cell Anatomy 0.000 claims description 76
- 241001465754 Metazoa Species 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 239000000411 inducer Substances 0.000 claims description 10
- 206010028851 Necrosis Diseases 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000017074 necrotic cell death Effects 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 239000002662 enteric coated tablet Substances 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000006215 rectal suppository Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102000018594 Tumour necrosis factor Human genes 0.000 claims 1
- 108050007852 Tumour necrosis factor Proteins 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 229940100618 rectal suppository Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 18
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000186216 Corynebacterium Species 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56120459A JPS5821621A (ja) | 1981-07-31 | 1981-07-31 | ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤 |
| SE8204382A SE8204382L (sv) | 1981-07-21 | 1982-07-19 | Sett att framstella malcellysfaktor och anvendning derav |
| FR8212541A FR2513124B1 (fr) | 1981-07-21 | 1982-07-19 | Production et applications du facteur de lyse des cellules-cibles |
| IT48855/82A IT1196549B (it) | 1981-07-21 | 1982-07-20 | Procedimento per la produzione del fattore di lisi cellule bersaglio (tclf),prodotto ottenuto a suo impiego in terapia clinica,in particolare come agente citolitico antitumurale |
| CH4420/82A CH664974A5 (fr) | 1981-07-21 | 1982-07-20 | Production du facteur de lyse des cellules-cibles. |
| KR8203215A KR870001433B1 (ko) | 1981-07-21 | 1982-07-20 | 적상적혈구(的狀赤血球) 붕괴인자의 제조 방법 |
| AU86200/82A AU560793B2 (en) | 1981-07-21 | 1982-07-20 | Production of target cell lysis factor |
| DE3249946A DE3249946C2 (de) | 1981-07-21 | 1982-07-21 | hTNF-haltiges therapeutisches Mittel gegen maligne Tumoren und dessen Verwendung |
| DE3227262A DE3227262C3 (de) | 1981-07-21 | 1982-07-21 | Verfahren zur Herstellung von menschlichem Tumor-Nekrose-Faktor und menschlicher Tumor-Nekrose-Faktor |
| GB08221100A GB2106117B (en) | 1981-07-21 | 1982-07-21 | Process for producing target cell lysis factor |
| US06/400,487 US4495282A (en) | 1981-07-21 | 1982-07-21 | Process for producing target cell lysis factor and uses therewith |
| ES514210A ES514210A0 (es) | 1981-07-21 | 1982-07-21 | Un procedimiento para la produccion de tclf. |
| AT0283582A AT387980B (de) | 1981-07-21 | 1982-07-21 | Verfahren zur herstellung eines die aufloesung menschlicher zellen bewirkenden faktors |
| CA000408532A CA1213544A (fr) | 1981-07-31 | 1982-07-30 | Procede de production de facteur de lyse de cellules cibles et utilisation |
| JP62028310A JP2518634B2 (ja) | 1981-07-31 | 1987-02-12 | ヒト ツモア・ネクロシス・フアクタ−の製造方法 |
| JP62028311A JP2518635B2 (ja) | 1981-07-31 | 1987-02-12 | ヒト ツモア・ネクロシス・フアクタ− |
| SE9000532A SE9000532L (sv) | 1981-07-21 | 1990-02-14 | Farmaceutisk tclf-komposition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56120459A JPS5821621A (ja) | 1981-07-31 | 1981-07-31 | ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62028310A Division JP2518634B2 (ja) | 1981-07-31 | 1987-02-12 | ヒト ツモア・ネクロシス・フアクタ−の製造方法 |
| JP62028311A Division JP2518635B2 (ja) | 1981-07-31 | 1987-02-12 | ヒト ツモア・ネクロシス・フアクタ− |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5821621A JPS5821621A (ja) | 1983-02-08 |
| JPS6245208B2 true JPS6245208B2 (fr) | 1987-09-25 |
Family
ID=14786690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56120459A Granted JPS5821621A (ja) | 1981-07-21 | 1981-07-31 | ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5821621A (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0764744B2 (ja) * | 1981-11-21 | 1995-07-12 | 株式会社林原生物化学研究所 | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 |
| US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| GR851626B (fr) * | 1984-07-05 | 1985-11-26 | Genentech Inc | |
| JP2675294B2 (ja) * | 1984-10-15 | 1997-11-12 | カイロン コーポレイション | ヒト腫瘍壊死因子 |
| JPS6248634A (ja) * | 1985-07-23 | 1987-03-03 | Mochida Pharmaceut Co Ltd | 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5816687A (ja) * | 1981-07-21 | 1983-01-31 | Hayashibara Biochem Lab Inc | リンホトキシンの製造方法 |
| GB2106117A (en) * | 1981-07-21 | 1983-04-07 | Mochida Pharm Co Ltd | Process for producing target cell lysis factor |
| JPS6011890A (ja) * | 1983-06-30 | 1985-01-22 | 富士通株式会社 | イメ−ジメモリ制御方式 |
-
1981
- 1981-07-31 JP JP56120459A patent/JPS5821621A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5816687A (ja) * | 1981-07-21 | 1983-01-31 | Hayashibara Biochem Lab Inc | リンホトキシンの製造方法 |
| GB2106117A (en) * | 1981-07-21 | 1983-04-07 | Mochida Pharm Co Ltd | Process for producing target cell lysis factor |
| JPS6011890A (ja) * | 1983-06-30 | 1985-01-22 | 富士通株式会社 | イメ−ジメモリ制御方式 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5821621A (ja) | 1983-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4285929A (en) | Type II interferon and agents thereof | |
| US4495282A (en) | Process for producing target cell lysis factor and uses therewith | |
| DK153848B (da) | Fremgangsmaade til fremstilling af interferon | |
| JPS6227048B2 (fr) | ||
| JPS586475B2 (ja) | ヒト絨毛性性腺刺激ホルモンの製造方法 | |
| JPS6245208B2 (fr) | ||
| JPS58107197A (ja) | ツモアネクロシスフアクタ−の製造方法 | |
| KR930004596B1 (ko) | 신규 림포킨(lymphokine) 및 이에 대해 특이성을 갖는 모노클로날(monoclonal) 항체의 제조 방법 | |
| JP2518634B2 (ja) | ヒト ツモア・ネクロシス・フアクタ−の製造方法 | |
| JPH0214039B2 (fr) | ||
| JP2518635B2 (ja) | ヒト ツモア・ネクロシス・フアクタ− | |
| US4624917A (en) | Process for the production of human T-cell growth factor | |
| KR950008569B1 (ko) | 신규 림포카인(lymphokine) 및 그 제조방법과 사용방법 | |
| JPH0764744B2 (ja) | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 | |
| JP2532025B2 (ja) | 新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤 | |
| JP2926409B2 (ja) | 癌転移抑制因子の製造方法 | |
| JPH0446928B2 (fr) | ||
| KR970002165B1 (ko) | γ-인터페론의 제조방법과 그 용도 | |
| JPH0523755B2 (fr) | ||
| JPH0527640B2 (fr) | ||
| JPS6045850B2 (ja) | ヒト副腎皮質刺激ホルモンの製法 | |
| JP2850293B2 (ja) | γ−インターフェロン感受性疾患剤 | |
| JPS61115028A (ja) | 抗腫瘍効果増強剤 | |
| KR820001174B1 (ko) | 사람 특이성 인터페론의 제조법 | |
| JPS6323176B2 (fr) |